Caseware UK (AP4) 2023.0.135 2023.0.135 2024-04-302024-04-30falsetrue2023-05-01falseNo description of principal activity2820trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 11923594 2023-05-01 2024-04-30 11923594 2022-05-01 2023-04-30 11923594 2024-04-30 11923594 2023-04-30 11923594 c:Director1 2023-05-01 2024-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2023-05-01 2024-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2024-04-30 11923594 d:Buildings d:LongLeaseholdAssets 2023-04-30 11923594 d:PlantMachinery 2023-05-01 2024-04-30 11923594 d:PlantMachinery 2024-04-30 11923594 d:PlantMachinery 2023-04-30 11923594 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923594 d:MotorVehicles 2023-05-01 2024-04-30 11923594 d:MotorVehicles 2024-04-30 11923594 d:MotorVehicles 2023-04-30 11923594 d:MotorVehicles d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923594 d:FurnitureFittings 2023-05-01 2024-04-30 11923594 d:FurnitureFittings 2024-04-30 11923594 d:FurnitureFittings 2023-04-30 11923594 d:FurnitureFittings d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923594 d:ComputerEquipment 2023-05-01 2024-04-30 11923594 d:ComputerEquipment 2024-04-30 11923594 d:ComputerEquipment 2023-04-30 11923594 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923594 d:OwnedOrFreeholdAssets 2023-05-01 2024-04-30 11923594 d:Goodwill 2023-05-01 2024-04-30 11923594 d:Goodwill 2024-04-30 11923594 d:Goodwill 2023-04-30 11923594 d:CurrentFinancialInstruments 2024-04-30 11923594 d:CurrentFinancialInstruments 2023-04-30 11923594 d:Non-currentFinancialInstruments 2024-04-30 11923594 d:Non-currentFinancialInstruments 2023-04-30 11923594 d:CurrentFinancialInstruments d:WithinOneYear 2024-04-30 11923594 d:CurrentFinancialInstruments d:WithinOneYear 2023-04-30 11923594 d:Non-currentFinancialInstruments d:AfterOneYear 2024-04-30 11923594 d:Non-currentFinancialInstruments d:AfterOneYear 2023-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2024-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2023-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2024-04-30 11923594 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2023-04-30 11923594 d:ShareCapital 2024-04-30 11923594 d:ShareCapital 2023-04-30 11923594 d:RetainedEarningsAccumulatedLosses 2024-04-30 11923594 d:RetainedEarningsAccumulatedLosses 2023-04-30 11923594 c:FRS102 2023-05-01 2024-04-30 11923594 c:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 11923594 c:FullAccounts 2023-05-01 2024-04-30 11923594 c:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 11923594 d:Goodwill d:ExternallyAcquiredIntangibleAssets 2023-05-01 2024-04-30 11923594 d:Goodwill d:OwnedIntangibleAssets 2023-05-01 2024-04-30 11923594 e:PoundSterling 2023-05-01 2024-04-30 iso4217:GBP xbrli:pure

Registered number: 11923594









WEELSBY VIEW PHARMACY LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2024

 
WEELSBY VIEW PHARMACY LTD
REGISTERED NUMBER: 11923594

BALANCE SHEET
AS AT 30 APRIL 2024

2024
2023
Note
£
£

Fixed assets
  

Intangible assets
  
617,720
-

Tangible assets
 5 
293,824
349,769

  
911,544
349,769

Current assets
  

Stocks
 6 
372,294
154,068

Debtors: amounts falling due after more than one year
 7 
47,711
-

Debtors: amounts falling due within one year
 7 
460,186
223,988

Cash at bank and in hand
 8 
362,260
298,438

  
1,242,451
676,494

Creditors: amounts falling due within one year
 9 
(423,635)
(214,734)

Net current assets
  
 
 
818,816
 
 
461,760

Total assets less current liabilities
  
1,730,360
811,529

Creditors: amounts falling due after more than one year
 10 
(632,671)
-

  

Net assets
  
1,097,689
811,529


Capital and reserves
  

Called up share capital 
  
100
100

Profit and loss account
  
1,097,589
811,429

  
1,097,689
811,529


Page 1

 
WEELSBY VIEW PHARMACY LTD
REGISTERED NUMBER: 11923594
    
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2024

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 28 January 2025.




Mr M Patel
Director

The notes on pages 3 to 11 form part of these financial statements.

Page 2

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

1.


General information

Weelsby View Pharmacy Ltd is a private company limited by shares. The company is incorporated in England & Wales and its registered office address is Aston House, Cornwall Avenue, London, N3 1LF. The registered number is 11923594.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

Page 3

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

  
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income ot to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.
The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in United Kingdom. 

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

 
2.5

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Intangible assets

Goodwill

Goodwill represents the difference between amounts paid on the cost of a business combination and the acquirer’s interest in the fair value of its identifiable assets and liabilities of the acquiree at the date of acquisition. Subsequent to initial recognition, goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised on a straight-line basis to the Statement of Income and Retained Earnings over its useful economic life.

Other intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

Page 4

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Long-term leasehold property
-
Straight Line Method for 10 years
Plant and machinery
-
25%
Reducing Balance Method
Motor vehicles
-
25%
Reducing Balance Method
Fixtures and fittings
-
25%
Reducing Balance Method
Computer equipment
-
25%
Reducing Balance Method

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Page 5

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

2.Accounting policies (continued)

 
2.12

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.13

Financial instruments

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of financial instruments.

Financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instruments any contract that evidences a residual interest in the assets of the Company after the deduction of all its liabilities.

Basic financial liabilities, which include trade and other payables, bank loans and other loans are initially measured at their transaction price after transaction costs. When this constitutes a financing transaction, whereby the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Discounting is omitted where the effect of discounting is immaterial.

Debt instruments are subsequently carried at their amortised cost using the effective interest rate method.

Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers. Trade payables are classified as current liabilities if the payment is due within one year. If not, they represent non-current liabilities. Trade payables are initially recognised at their transaction price and subsequently are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial.


3.


Employees

The average monthly number of employees, including directors, during the year was 28 (2023 - 20).

Page 6

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

4.


Intangible assets




Goodwill

£



Cost


Additions
686,355



At 30 April 2024

686,355



Amortisation


Charge for the year on owned assets
68,635



At 30 April 2024

68,635



Net book value



At 30 April 2024
617,720



At 30 April 2023
-



Page 7

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

5.


Tangible fixed assets





Long-term leasehold property
Plant and machinery
Motor vehicles
Fixtures and fittings
Computer equipment

£
£
£
£
£



Cost or valuation


At 1 May 2023
242,989
157,211
7,079
47,109
-


Additions
-
-
-
12,729
4,797



At 30 April 2024

242,989
157,211
7,079
59,838
4,797



Depreciation


At 1 May 2023
60,748
26,056
2,101
15,714
-


Charge for the year on owned assets
30,374
32,789
1,244
8,571
493



At 30 April 2024

91,122
58,845
3,345
24,285
493



Net book value



At 30 April 2024
151,867
98,366
3,734
35,553
4,304



At 30 April 2023
182,241
131,155
4,978
31,395
-
Page 8

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

           5.Tangible fixed assets (continued)


Total

£



Cost or valuation


At 1 May 2023
454,388


Additions
17,526



At 30 April 2024

471,914



Depreciation


At 1 May 2023
104,619


Charge for the year on owned assets
73,471



At 30 April 2024

178,090



Net book value



At 30 April 2024
293,824



At 30 April 2023
349,769


6.


Stocks

2024
2023
£
£

Finished goods and goods for resale
372,294
154,068

372,294
154,068


Page 9

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

7.


Debtors

2024
2023
£
£

Due after more than one year

Other debtors
47,711
-

47,711
-


2024
2023
£
£

Due within one year

Trade debtors
323,190
169,987

Amounts owed by group undertakings
20,000
20,000

Other debtors
56,753
32,254

Prepayments and accrued income
60,243
1,747

460,186
223,988



8.


Cash and cash equivalents

2024
2023
£
£

Cash at bank and in hand
362,260
298,438

362,260
298,438



9.


Creditors: Amounts falling due within one year

2024
2023
£
£

Bank loans
124,001
-

Trade creditors
196,546
149,437

Corporation tax
80,150
42,641

Other taxation and social security
2,281
5,595

Other creditors
14,616
11,265

Accruals and deferred income
6,041
5,796

423,635
214,734


Page 10

 
WEELSBY VIEW PHARMACY LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2024

10.


Creditors: Amounts falling due after more than one year

2024
2023
£
£

Bank loans
322,562
-

Amounts owed to group undertakings
310,109
-

632,671
-



11.


Loans


Analysis of the maturity of loans is given below:


2024
2023
£
£

Amounts falling due within one year

Bank loans
124,001
-


124,001
-

Amounts falling due 1-2 years

Bank loans
124,001
-


124,001
-

Amounts falling due 2-5 years

Bank loans
198,561
-


198,561
-


446,563
-


 
Page 11